Inhibiting sEH suppresses NF-κB p65 signaling and reduces CXCL10 expression as a potential therapeutic target in HT.
Jing FengXianghong XuWei CaiXingwen YangRuilan NiuZiqi HanLimin TianPublished in: The Journal of clinical endocrinology and metabolism (2024)
Our findings suggest that sEH/NF-κB p65/CXCL10-CXCR3 might be promising therapeutic targets for HT.